We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

GMP PROTEIN (E. COLI) CONTRACT MANUFACTURING MARKET ANALYSIS

GMP Protein (E. coli) Contract Manufacturing Market, by Product Type (Cytokines, Growth Factors, Enzymes [DNA polymerase, Protease, Trypsin, Nuclease {Benzonase, Cas9 Nucleases, and Others}, IVT Enzymes, and Others] Hormones, Antigens, and Others), by Application (Gene Therapy and Cell Therapy), by Method (In-Vivo and Ex-Vivo), by End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • Published In : Dec 2022
  • Code : CMI5433
  • Pages :603
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

GMP Protein (E. coli) Contract Manufacturing MarketSize and Trends

Proteins are manufactured under guidelines that allow for their use as ancillary materials in cell therapy or further manufacturing processes. GMP proteins also come with extensive documentation and traceability, as well as additional quality control testing. Global GMP protein (E. coli) contract manufacturing market is estimated to be valued at US$ 685.8 million in 2022 and is expected to exhibit a CAGR of 9.7% during the forecast period (2022-2030).

Figure 1. Global GMP Protein (E. coli) Contract Manufacturing Market Share (%), by Application, 2022

Global GMP Protein (E. coli) Contract Manufacturing Market- Drivers

Increasing research and development activities by key market players are expected to drive market growth over the forecast period. For instance, according to Alliance for Regenerative Medicine, 2020, approximately US$ 9.8 billion was raised in global financings for the cell and gene therapy sector in 2019. Moreover, according to the same source, in 2020, there were 572 ongoing regenerative medicine clinical trials in U.S. trial sites.

Increasing inorganic growth strategies by the key players to increase GMP grade protein production capacities is expected to drive market growth over the forecast period. For instance, in October 2021, Avid Bioservices, Inc., a dedicated biologics Contract Development and Manufacturing Organization (CDMO), announced that the company is increasing its CDMO service offering in the rapidly growing cell and gene therapy market. As part of this effort, the company is constructing a world-class, purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA, approximately five miles from Avid’s existing operations in Tustin, CA.

Figure 2. Global GMP Protein (E. coli) Contract Manufacturing Market Share (%), by Region, 2022

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.